Erectile Dysfunction Drugs Market Size Is Estimated To Reach $3.2 Billion By 2022: Grand View Research, Inc.

The global erectile dysfunction drugs market is expected to reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market. 

However, the market is estimated to witness decline in revenue over the forecast period. Expiration of key drugs from 2017 to 2019 is likely to curb revenue growth. On the other hand, the market is likely to open up new avenues for the generic manufacturers to capitalize on. The increasing risk of sexually transmitted diseases, narrowing of insurance coverage for erectile dysfunction treatment, growing threat from counterfeit drugs, and presence of social stigma in developing countries are some factors limiting penetration rates. 

North America erectile dysfunction drugs market, by product, 2012 - 2022, (USD Million)





Browse full research report on Erectile Dysfunction Drugs Market: http://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market                  
      
Further key findings from the report suggest:

  • Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and advantages associated with this drug such as high efficacy, and effectiveness are the major factors attributing for its large market share.
  • Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a prescription drug in the U.S. Cialis is also known as “The Weekend Pill” owing to its 36-hour effectiveness.
  • After the patent expiration of key drugs such as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil Cream) are expected to capture the market share during the forecasts period.
  • North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecasts period.
  • Asia Pacific accounted for a revenue share of over 16.5% in 2012 owing to the presence of a lucrative market for generic drugs, untapped opportunities, and increasing awareness related to erectile dysfunction in this region
  • Apricus Biosciences Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co. Ltd., and Vivus, Inc. are some major players of this market
  • Extensive R&D carried out by companies and high unmet needs in developing economies are expected to boost industrial growth. Key manufacturers are targeting regions with unmet clinical needs by entering into agreement with local manufacturers and distributors. Key players are constantly engaged in developing novel drugs in an attempt to improve the presence and ensure sustainability. 

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals        
     
Grand View Research has segmented the global erectile dysfunction drugs market on the basis of product and region:

Erectile Dysfunction Drugs Product Outlook (Revenue, USD Million, 2012 – 2022)
  • Viagra (sildenafil citrate)
  • Cialis (tadalafil)
  • Levitra/Staxyn (vardenafil)
  • Stendra/Spedra (avanafil)
  • Zydena (udenafil)
  • Vitaros (Alprostadil Cream)
  • Others
Erectile Dysfunction Drugs Regional Outlook (Revenue, USD Million, 2012 – 2022)
  • North America
  • Europe
  • Asia Pacific
  • RoW

                    
About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: http://www.grandviewresearch.com

Comments

Popular posts from this blog

The global vein illuminator market is expected to reach USD 358.5 million by 2024, according to a new report published by Grand View Research, Inc. The vein illuminator market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing aging population and the efforts channelized towards improving patient satisfaction. Additionally, factors, such as the demand for technologically advanced medical equipment and the rising research and practical applications are expected to be opportunistic for the industry growth. However, the prevalence of traditional methods owing to the high costs of the vein illuminator devices is likely to hinder the growth of the market in the near future. The vein illuminator market is segmented on the basis of technology, application, end-user, and region. Based on technology, the market is further categorized into transillumination, infrared technology, and ultrasound. The near-infrared illumination technology is estimated to be the largest shareholder due to its ability to penetrate deep into the tissue, which makes it possible to visualize the vessels clearly. On the basis of application, the market is segmented into intravenous access and blood draw. The end-user segment comprises hospitals, rehabilitation facilities, blood donation camps, and academic institutions. The market for hospitals is expected to grow rapidly during the forecast period due to a surge in the demand for technologically advanced medical equipment. The market is also categorized into North America, Europe, Asia Pacific, MEA, and Latin America. Browse full research report on global Vein Illuminator Market: http://www.grandviewresearch.com/industry-analysis/vein-illuminator-market Further key findings from the study suggest: • In terms of market share, the North America vein illuminator market is expected to hold majority of the share in 2016. Factors resulting in the growth of this industry are the steady preference for highly-advanced medical devices by hospitals as well as the presence of several medical device manufacturing companies in the region. • The infrared illumination technology is estimated to lead the industry due to its deep penetration capability into thick tissues tohighlight the presence of vessels with increased clarity. Based on application, the segment for intravenous access is estimated to be the largest shareholder, followed by the blood draw segment. • The vein illuminator industry comprises several local as well as global players. Some prominent players in this industry include Accuvein, Inc., Christie Medical Holdings, Inc., Infrared Imaging Systems, Inc., Translite, LLC, and Venoscope, LLC,among others. In order to hold a major share in the industry, the companies are adopting both organic as well as inorganic strategies. The major strategies adopted by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. • The companies are also focusing on research and development activities in order to enhance their product portfolio. For instance, in September 2015, Accuvein, Inc., declared its 26th patent, which was issued by the United States Patent and Trademark office for their vein visualization system. Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices Grand View Research has segmented the vein illuminator market on the basis of technology, application, and end-user application: Vein Illuminator Technology Outlook (Revenue, USD Million, 2013 - 2024) • Transillumination • Infrared technology • Others Vein Illuminator Application Outlook (Revenue, USD Million, 2013 - 2024) • Intravenous access • Blood draw • Others Vein Illuminator End-user Outlook (Revenue, USD Million, 2013 - 2024) • Hospitals • Blood donation camps • Academic institutions • Others Vein Illuminator Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • Europe • Asia Pacific • Latin America • MEA Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-vein-illuminator-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc For more information: www.grandviewresearch.com

Hyaluronic Acid Market Is Likely To Be Influenced By The Increase In Obesity Till 2024: Grand View Research, Inc.

Protein Purification & Isolation Market Is Predicted To Grow Swiftly Due To Increased Research In The Fields Of Biotechnology & Pharmaceuticals Till 2025: Grand View Research, Inc.